Novel polymorph of niraparib oxalate and method of preparation
The novel Niraparib Oxalate Form O addresses the need for improved pharmaceutical formulations by offering high purity and stability, enhancing solubility and bioavailability through a specific preparation process.
Patent Information
- Application Number
- PCT/TR2025/050492
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
There is a need for new salts of niraparib with improved physical and chemical properties to enhance the characteristics of pharmaceutical formulations, particularly in terms of solubility, dissolution rate, drug absorption, and bioavailability.
The development of a novel crystalline polymorphic form of Niraparib Oxalate, designated as Form O, characterized by specific XRPD peaks and prepared through a process involving mixing niraparib with oxalic acid in suitable solvents, followed by stirring and filtration, resulting in high purity and stability.
Niraparib Oxalate Form O exhibits high purity and stability under various conditions, maintaining its crystalline form and chemical integrity, thus improving the quality and efficacy of pharmaceutical compositions.
Smart Images

Figure IMGF000001_0001 
Figure IMGF000004_0001 
Figure IMGF000010_0001
Abstract
Description
[0001] DESCRIPTION
[0002] NOVEL POLYMORPH OF NIRAPARIB OXALATE AND METHOD OF PREPARATION
[0003] Technical Field
[0004] The present invention refers to a novel crystalline polymorphic form of Niraparib Oxalate designated as Form O and a process for its preparation.
[0005] The invention further relates to pharmaceutical compositions containing Niraparib Oxalate Form O and its use for the treatment of cancer.
[0006] Background Art
[0007] Niraparib is chemically known as 2-{4-[(35)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (CAS No: 1038915-60-4) and represented by the following structural formula:
[0008]
[0009] Niraparib
[0010] Niraparib is a potent poly (ADP-ribose) polymerase (PARP) inhibitor clinically approved for the treatment of ovarian, breast, and other cancers associated with BRCA mutations. It is marketed under the brand name Zejula in the European Union, the United States, and various other countries.
[0011] ZEJULA (Niraparib) tablets contains 159.3 mg, 318.7 mg, or 478.0 mg of niraparib tosylate monohydrate equivalent to 100 mg, 200 mg, or 300 mg, respectively, of niraparib free base as the active ingredient.
[0012] ZEJULA (Niraparib) capsule contains 159.4 mg niraparib tosylate monohydrate equivalent to 100 mg niraparib free base as the active ingredient
[0013] Niraparib and pharmaceutically acceptable salts thereof, first disclosed in International Publication Nos. W02007113596 and W02008084261. Further the application discloses processes for the preparation of niraparib, pharmaceutical preparation of niraparib and therapeutic application thereof.
[0014] US Patent No. US8436185 discloses tosylate monohydrate salt of niraparib and furtherdiscloses sulfate, benzenesulfate, fumarate and succinate salts of niraparib. In 2017, the U.S. FDA approved the company's niraparib tosylate monohydrate (1:1:1), under the trade name ZEJULA.
[0015] International Publication Nos. WO2014 / 088983 and WO2014 / 088984 disclose methods of making niraparib and pharmaceutically acceptable salts thereof.
[0016] International Publication No. WO 2018200517 discloses methods for the preparation of niraparib tosylate monohydrate
[0017] Several salts of niraparib including various crystalline forms are disclosed.
[0018] WO2018183354 dicloses Form I, Form II and Form III of Niraparib tosylate, each substantially free of the other two forms.
[0019] WO 2020072796 discloses crystalline Form I, Form II, Form III, Form IV and Form V of Niraparib free base.
[0020] WO 2020072860 discloses crystalline anhydrous Form A of Niraparib tosylate.
[0021] Other salts described are -hydroxyphenyl glycinate (CN 106432187), N-acetyl- / .-leucinate (CN106467513) and / .-tartrate (CN106496187), used for the enantiomeric separation of racemic niraparib.
[0022] Different salts and solid state forms of an active pharmaceutical ingredient may possess different properties.
[0023] The discovery of a new salt of an active substance provides an opportunity to improve its characteristics, increasing the possibilities available to a formulation specialist when developing a new pharmaceutical form, a drug with a particular release profile or a specific dissolution degree.
[0024] Based on these considerations, there still appears a need for new salts of niraparib having further improved physical and / or chemical properties. Hence it was thought worthwhile by the inventors of the present application to explore pharmaceutically novel salts of niraparib with good chemical purity and improved stability characteristics, which may further improve the characteristics of niraparib in finished medicinal product.
[0025] Summary of the invention
[0026] The object of the present invention is to provide crystalline form of Niraparib Oxalate Form O, processes for preparation thereof, and pharmaceutical compositions thereof.
[0027] Technical Problem
[0028] Active pharmaceutical ingredients are individual components that are used as a part of a finished pharmaceutical drug or medicinal product, where they provide the pharmacologicalactivity.
[0029] Research and development projects in the pharmaceutical industry mainly aim to investigate different possible salts, polymorphs and processes to produce active pharmaceutical ingredients.
[0030] Salt formation in general is vitally important in drug substance synthesis as well as overall pharmaceutical development and manufacture.
[0031] Salt forms of drug substances have significant effects on physicochemical properties of the drug influencing its quality, safety, and performance.
[0032] Polymorphism, the occurrence of different crystal forms, is a property of some molecules and molecular complexes. A single molecule, may give rise to a variety of crystalline forms having distinct crystal structures and physical properties like melting point, thermal behaviors, X-ray powder diffraction (XRPD) pattern, Infrared absorption fingerprint, Raman absorption fingerprint, and solid state (13C) NMR spectrum. One or more of these techniques may be used to distinguish different polymorphic forms of a compound. Difference in the physical properties of different crystalline forms results from the orientation and intermolecular interactions of adjacent molecules or complexes in the bulk solid.
[0033] The relationship between polymorphic forms of pharmaceutically active ingredient and pharmaceutical product is well known in the pharmaceutical industry. Pharmaceutical formulation is affected by polymorphic form of the pharmaceutically active ingredient.
[0034] Discovery of new salts and polymorphic forms of an active pharmaceutical ingredient provides a new opportunity to improve solubility, dissolution rate, drug absorption and bioavailability of pharmaceutical finished product, therefore, development of new salts and polymorphic forms are always encouraged.
[0035] According to the need, studies have been done to develop novel salts of niraparib and novel polymorphs of niraparib having advantageous properties, which are useful and suitable for the preparation of various pharmaceutical compositions.
[0036] Solution to Problem
[0037] The present disclosure includes novel polymorph of Niraparib Oxalate.
[0038] These new polymorph of Niraparib Oxalate, besides being stable, meets the pharmaceutical requirements such as storage, shelflife and high purity.
[0039] Description of embodiments
[0040] The first aspect of the present invention is to provide a novel crystalline form of NiraparibOxalate and its process for the preparation thereof.
[0041]
[0042] Niraparib Oxalate
[0043] This new form hereinafter designated as “Form-0”. Form O is characterized by an XRPD pattern having characteristic peaks 14.14, 16.27. 17.69, 19.29, 21.43, 21.97, 22.79, 25.06, 26.43, and 28.93 ± 0.2 degree 2-theta. Form O is characterized by an XRPD pattern, as shown in Figure 1 and 2-theta values as shown in Table 1.
[0044] Table 1. Characteristic 2-theta values ofNiraparib Oxalate (Form O)
[0045]
[0046] The second aspect of the present invention is to provide Niraparib Oxalate (Form O) and its process for the preparation thereof.
[0047] Described is a process for the preparation of crystalline Form O of Niraparib Oxalate which comprises:
[0048] a) mixing niraparib with suitable solvent at a suitable temperature,
[0049] b) adding oxalic acid and / or its solution into the niraparib mixture at step (a)
[0050] c) stirring the reaction solution at step (b) at a suitable temperature and suitable time. d) filtering to isolate the obtained solid,
[0051] 5e) washing the obtained solid as pure crystalline Form O with a suitable solvent.
[0052] Wherein suitable solvent in step (a), step (b) and step (e) is selected from, water, methanol, ethanol, propanol, butanol, tert-butyl alcohol, acetone, butanone, 2-pentanone, 3 -pentanone and acetophenone or mixtures thereof.
[0053] The suitable temperature used in step (a) and step (c) is room temperature.
[0054] The suitable time used in step (c) is between 2-16 hours.
[0055] The degree of purity of the active ingredient and the resulting possible changes of the efficacy, further important properties for the pharmaceutical processing can be affected in an adverse manner.
[0056] The process of the present invention affords crystalline Form O in high purity and high yield. The crystalline Form O is obtained having purity greater than 99.94% by area percentage in high-performance liquid chromatograph (HPLC).
[0057] Stability plays an important role in the drug development process. Stability of a pharmaceutical product may be defined as the capability of that particular formulation, in a specific container or closure system, to remain within its chemical, physical, microbiological, therapeutic and toxicological specifications to assure its attributed quality, e.g., identity, purity, strength etc. until drug expiry.
[0058] Stability of a pharmaceutical product is strongly influenced by changes in solid-state form of the drug substance. The changes in solid state form of the drug substance may be resulted from the conditions of manufacturing process. Examples of processing that may cause polymorphic changes including grinding, milling, heating, and applying compression. Manufacturing conditions that include a solvent (e.g., wet granulation, polymorphs in solution, and polymorphs in suspension) may facilitate changes in the solid-state form of drug substance. These variations comprising polymorphic transformations, hydrate / solvate formations and dehydration / desolvation reactions in the solid-state form of the drug substance, may cause stability problems in finished pharmaceutical products. Therefore, crystalline stability of the drug substance has a critical role on satisfying the essentialities of qualified pharmaceutical product and stable polymorphs of drug substance should be used in pharmaceutical formulations.
[0059] For a third aspect of the present invention, crystalline stability of crystalline Form O as Niraparib Oxalate was investigated under the condition 25 °C, 60% relative humidity (RH) for 6 months after preparation.
[0060] The crystalline stability referred to here, is the stability of a polymorphic form of API withrespect to polymorph transformations, hydration or dehydration, salt disproportionation, crystallization, or amorphization through time under the condition 25 °C, 60% RH for 6 months after preparation.
[0061] The crystalline stability of Niraparib Oxalate Form O is investigated and determined by X-ray powder diffraction method. Results show that any polymorphic transformation to another crystal form or any degradation in crystalline Niraparib Oxalate Form O did not occur. Crystalline Niraparib Oxalate Form O shows crystalline stability under 25 °C, 60% RH for 6 months. X-ray diffractogram of crystalline Niraparib Oxalate Form O kept under the conditions at 25 °C, 60% RH for 6 months is given in Fig. 5 clearly shows that 2-theta values of characteristic peaks did not change when exposed to accelerated stability conditions.
[0062] The chemical stability of crystalline Niraparib Oxalate Form O is also important and its stability in finished product at room-temperature storage can be predicted from shorter-term storage under accelerated conditions of high temperature and humidity.
[0063] In the present invention, samples of obtained crystalline Niraparib Oxalate Form O are stored for 6 months in stability chambers under following condition of 25 °C 60% to test chemical stability. The chemical stability of the samples was determined by HPLC method and appearance solution test according to reference solution.
[0064] Table 2 shows the stability results of Niraparib Oxalate Form O prepared according to the present invention in comparison to Niraparib Tosylate (NTs) Form I prepared according to US8436185. Niraparib Oxalate Form O and NTs Form I were kept at 25°C and 60% relative humidity conditions for 6 months. At 25°C and 60 % RH condition, initial total impurity amounts were 0.06% for Niraparib Oxalate Form O and 0.26% for NTs Form I. The total impurity amounts at the end of 6 months were 0.12% for Niraparib Oxalate Form O and 0.27% for NTs Form I. The total impurity levels indicate that both forms exhibit similar stability. Test of appearance and appearance of solution is stable both forms during 6 month storage condition.
[0065] Table 2. Niraparib stability test results of Form O versus NTs
[0066]
[0067] *Packed samples were kept at 25 °C and 60% relative humidity**Prepared according to US8436185 patent
[0068] In addition to examining relative humidity conditions, forced degradation studies were conducted to assess the crystalline stability of Niraparib Oxalate Form O. Forced degradation tests are studies used to assess the stability of active pharmaceutical ingredients (APIs) and their formulations. These tests are performed submitting the API under extreme conditions in order to know the main degradation products in a short period.
[0069] Table 3 shows the stability results of Niraparib Oxalate Form O prepared according to the present invention in comparison to NTs Form I prepared according to US8436185. Niraparib Oxalate Form O and NTs Form I were kept at 105°C for 15 days, day light and UV light for 25 days. The initial total impurity amounts were 0.06% for Niraparib Oxalate Form O and 0.26% for NTs Form I. Thermal decomposition was detected at temperatures of 105°C. The total impurity amounts for the thermal degradation results were 0.09% for Form Niraparib Oxalate Form O and 0.28% for NTs Form I.
[0070] No specific degradation was observed for Niraparib Oxalate Form O when exposed to daylight and UV light. The total impurity amounts for the day light results were 0.27% for NTs Form I. The total impurity amounts for the UV-light results were 0.27% for NTs Form I.
[0071] The total impurity amounts showed that Niraparib Oxalate Form O exhibit similar stability with NTs Form I.
[0072] Table 3. Niraparib forced degradation results of Niraparib Oxalate Form O versus NTs Form I
[0073]
[0074] Brief description of the drawings:
[0075] Figure 1 shows the X-ray powder diffraction (XRPD) pattern of crystalline Niraparib Oxalate Form O
[0076] Figure 2 shows the 'H NMR spectrum of Niraparib Oxalate
[0077] Figure 3 shows the13C NMR spectrum of Niraparib Oxalate
[0078] Figure 4 shows the differential scanning calorimetric (DSC) curve of Niraparib Oxalate Form O
[0079] Figure 5 shows X-Ray Powder Diffraction (XRPD) pattern of Niraparib Oxalate Form O (25 °C, 60% RH for 6 months)
[0080] Figure 6 shows the 'H NMR spectrum of Niraparib THF solvate
[0081] Figure 7 shows the13C NMR spectrum of Niraparib THF solvate
[0082] Instrumental parameters:
[0083] NMR:
[0084] 'H NMR, and13C NMR analyses were performed on a 400 MHz NMR spectrometer (JEOL Ltd., Tokyo, Japan) using deuterated dimethyl sulfoxide (DMSO-tL) as a solvent.
[0085] DSC:
[0086] Differential scanning calorimetry (DSC) thermogram was obtained using a differential scanning calorimeter (TA instruments DSC 250, USA) by using following instrument parameters: Start temperature: 25 °C, final temperature: 350 °C, heating rate: 10 °C / min.
[0087] PXRD:
[0088] X-Ray powder diffractograms were measured using a Shimadzu Lab-X XRD-6100 X-ray diffractometer (Shimadzu Corporation, Japan) by using following instrument parameters: The measurement conditions were as follows:
[0089] Radiation: Cu (1.5406 A)
[0090] Filter for KP: Nickel
[0091] Voltage: 40.0 kV
[0092] Current: 30.0 Ma
[0093] Auto slit: not used
[0094] Divergence slit: 1.0°
[0095] Scatter slit: 1.0°
[0096] Receiving slit: 0.30 mm with a Graphite monochromatic
[0097] Drive axis: Theta-2ThetaScan range: 3.00 -40.00°
[0098] Scan mode: continuous scan
[0099] Scan speed: 1.07min
[0100] Sampling pitch: 0.02°
[0101] HPLC for the reaction conversion and purity:
[0102] Equipment: Shimadzu LC-2030 Plus system equipped with an SPD-40 V detector
[0103] Column: Waters HSS T3 150 x 4.6 mm, 3,5pm.
[0104] Column temperature: 40 °C
[0105] Sample temperature: 5 °C
[0106] Injection volume: 20 pL
[0107] Flow rate: 1.0 mL / min.
[0108] Elution: Gradient
[0109] Gradient Program
[0110] Mobile Phase: A: 10 mM KH2PO4pH: 5.2 , B: ACN; Eluent: %80 MeOH
[0111]
[0112] Following examples are provided to enable one skilled in the art to practice the invention and are merely illustrative of the invention. The examples should not be read as limiting the scope of the invention.
[0113] 10EXAMPLES
[0114] Example-1: Synthesis of Niraparib ((5)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide)
[0115]
[0116] A I L two-necked, round bottomed flask equipped with a magnetic stir bar and a dropping funnel was charged with fS')- tert-butyl 3-(4-(7-carbamoyl-2H-indazol-2-yl)phenyl)piperidine-1-carboxylate (50.5 g, 0.12 mol, 1.00 eq) and THF (400 mL). After cooling the reaction solution in an ice bath, the dropping funnel was filled with 73,5 mL of saturated HC1 (32%, 10.2 M, 0.72 mol, 6.00 eq), which was drop by drop added to the reaction mixture over 30 minutes. After completion of adding the HC1 solution, the ice bath was removed and the reaction solution was stirred for 12h at room temperature. pH of the aqueous solution was adjusted to between 7-8 with 30% NaOH solution while maintaining the temperature 20°C. THF was removed by rotary evaporation until 50 mL remained and the pH of the mixture was adjusted between 11-12 with 4N NaOH solution. After occuring a precipitation, the mixture was stirred for 2 hours. The precipitate was filtered and washed with water (3x25mL) and acetone (2x25 mL). The resulting white solid was dried under vacuum at 50 °C for 4 h to afford Niraparib (2, 35.5 g, 92.2%) as its THF solvate. 'H NMR (400 MHz, DMSO-6) = 9.26 (s, 1H), 8.58 (d, J = 3.0 Hz, 1H), 8.10 - 7.98 (m, 4H), 7.89 (d, J = 2.9 Hz, 1H), 7.50 - 7.41 (m, 2H), 7.26 (dd, J= 8.3, 7.0 Hz, 1H), 3.62-3.56 (m, 2H, THF), 3.05 - 2.89 (m, 2H), 2.69 (tt, J= 11.2, 3.6 Hz, 1H), 2.59 - 2.43 (m, 4H), 1.95 - 1.86 (m, 1H), 1.79 - 1.70 (m, 2H, THF), 1.70 - 1.40 (m, 3H). °CNMR(100MHz, DMSO-tZ5) 5 (ppm) = 166.04 (C), 146.51 (C), 146.23 (C), 138.02 (C), 130.11 (CH), 128.75 (CH), 125.75 (CH), 123.88 (C), 123.77 (CH), 122.33 (CH), 121.93 (C), 121.17 (CH), 67.48 (CH2; THF), 54.03 (CH2), 46.45 (CH2), 43.60 (CH), 32.33 (CH2), 27.05 (CH2), 25.59 (CH2; THF).
[0117] Example-2: Oxalate salt; (5)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide oxalate
[0118]
[0119] A solution of (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide (10 g, 31.2 mmol, 1.00 eq) in Acetone (75 mL) was stirred for 0.5h at room temperature. Oxalic acid (3.1 g, 34.32 mmol, 1.10 eq) was portionwise added to the solution and stirred for 16h at room temperature. The obtained precipitate was filtered and washed with Acetone (25 mL). The resulting white solid underwent vacuum drying at 60°C for 6 hours, Niraparib Oxalate (12.2 g, 95%; purity: 99.94%). 'H NMR (400 MHz, DMSO-6) = 59.32 (s, 1H), 8.56 (d, J= 2.9 Hz, 1H), 8.13 (d, J = 8.2 Hz, 2H), 8.05 (ddd, J = 15.9, 7.7, 1.1 Hz, 2H), 7.94 (d, J= 2.9 Hz, 1H), 7.54 (d, J= 8.3 Hz, 2H), 7.27 (dd, J = 8.4, 7.0 Hz, 1H), 3.36 (dd, J = 17.1, 10.4 Hz, 2H), 3.08 (d, J = 9.2 Hz, 2H), 2.92 (t, J= 11.4 Hz, 1H), 1.97 - 1.88 (m, 2H), 1.84 - 1.68 (m, 2H). °C NMR (100 MHz, DMSO-tf5) 5 (ppm) = 166.06 (C), 164.24 (C), 146.64 (C), 142.78 (C), 138.83 (C), 130.33 (CH), 129.05 (CH), 125.90 (CH), 124.01 (CH), 123.97 (C), 122.51 (CH), 122.04 (C), 121.50 (CH), 48.29 (CH2), 43.43 (CH2), 39.25 (CH), 29.96 (CH2), 22.84 (CH2).
[0120] 12
Claims
CLAIMS1. A crystalline Form O of Niraparib Oxalate wherein the X-ray powder diffraction pattern is as defined by the following table:
2. The crystalline Form O of Niraparib Oxalate according to claim 1, wherein the X-ray powder diffraction pattern is as shown in Figure 1.
3. A process for the synthesis of crystalline Form O of Niraparib Oxalate according to claim 1 or 2 comprising:f) mixing niraparib with suitable solvent at a suitable temperature,g) adding oxalic acid and / or its solution into the niraparib mixture at step (a)h) stirring the reaction solution at step (b) at a suitable temperature,i) filtering to isolate the obtained solid,j) washing the obtained solid as pure crystalline Form O with a suitable solvent.
4. A pharmaceutical composition comprising crystalline Form O of Niraparib Oxalate and optionally at least one pharmaceutically acceptable excipient.
5. A medicament for the treatment of cancer comprising administering a therapeutically effective amount of crystalline Form O of Niraparib Oxalate.
6. A method of treating cancer comprising administering a therapeutically effective amount of crystalline Form O of Niraparib Oxalate, wherein the crystalline Form O of Niraparib Oxalate is characterized by an XPRD pattern having 2-theta values as shown in Fig. 1.
